Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 03, 2023

Efficacy of Lorlatinib in Treatment-Naïve Patients With ALK-Positive Advanced NSCLC Based on EML4-ALK Variant Type and TP53 Mutational Status

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations
J Thorac Oncol 2023 Aug 02;[EPub Ahead of Print], A Bearz, JF Martini, J Jassem, SW Kim, GC Chang, AT Shaw, DA Shepard, E Dall'O', A Polli, H Thurm, G Zalcman, MR Garcia Campelo, K Penkov, H Hayashi, B Solomon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading